169 related articles for article (PubMed ID: 37893593)
1. More Than Meets the Eye: A Case of Breast Cancer Switching from Being Luminal-Androgen-Receptor-Positive to Being Hormone-Receptor-Positive.
Martorana F; Di Grazia G; Rosano GN; Vecchio GM; Conti C; Nucera S; Magro G; Vigneri P
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893593
[TBL] [Abstract][Full Text] [Related]
2. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
[TBL] [Abstract][Full Text] [Related]
4. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
Vtorushin S; Dulesova A; Krakhmal N
J Zhejiang Univ Sci B; 2022 Aug; 23(8):617-624. PubMed ID: 35953756
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
Gerratana L; Basile D; Buono G; De Placido S; Giuliano M; Minichillo S; Coinu A; Martorana F; De Santo I; Del Mastro L; De Laurentiis M; Puglisi F; Arpino G
Cancer Treat Rev; 2018 Jul; 68():102-110. PubMed ID: 29940524
[TBL] [Abstract][Full Text] [Related]
6. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.
Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
[TBL] [Abstract][Full Text] [Related]
7. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
Sharifi MN; O'Regan RM; Wisinski KB
Clin Breast Cancer; 2023 Dec; 23(8):813-824. PubMed ID: 37419745
[TBL] [Abstract][Full Text] [Related]
8. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.
Xu F; Xu K; Fan L; Li X; Liu Y; Yang F; Zhu C; Guan X
Chin Med J (Engl); 2024 Feb; 137(3):338-349. PubMed ID: 38105538
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
11. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
12. In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines.
Kumar S; Bhattacharyya S; Das A; Singh G; Bal A
Breast Dis; 2022; 41(1):241-247. PubMed ID: 35431224
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
14. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.
Leeha M; Kanokwiroon K; Laohawiriyakamol S; Thongsuksai P
Pathol Oncol Res; 2023; 29():1611162. PubMed ID: 37274773
[No Abstract] [Full Text] [Related]
16. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
17. Role of androgen and microRNA in triple-negative breast cancer.
Al-Othman N; Ahram M; Alqaraleh M
Breast Dis; 2020; 39(1):15-27. PubMed ID: 31839601
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.
Kucukzeybek BB; Bayoglu IV; Kucukzeybek Y; Yıldız Y; Oflazoglu U; Atahan MK; Taskaynatan H; Alacacioglu A; Yigit S; Tarhan MO
Pol J Pathol; 2018; 69(2):157-168. PubMed ID: 30351863
[TBL] [Abstract][Full Text] [Related]
19. Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype.
Asemota S; Effah W; Young KL; Holt J; Cripe L; Ponnusamy S; Thiyagarajan T; Hwang DJ; He Y; Mcnamara K; Johnson D; Wang Y; Grimes B; Khosrosereshki Y; Hollingsworth TJ; Fleming MD; Pritchard FE; Hendrix A; Khan F; Fan M; Makowski L; Yin Z; Sasano H; Hayes DN; Pfeffer LM; Miller DD; Narayanan R
Cell Rep; 2023 Dec; 42(12):113461. PubMed ID: 37979170
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
Di Leone A; Fragomeni SM; Scardina L; Ionta L; Mulè A; Magno S; Terribile D; Masetti R; Franceschini G
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1910-1915. PubMed ID: 33660830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]